Meropenem - B Braun Medical

Drug Profile

Meropenem - B Braun Medical

Latest Information Update: 25 Jul 2016

Price : $50

At a glance

  • Originator B Braun Medical
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial meningitis; Intra-abdominal infections; Skin and soft tissue infections

Most Recent Events

  • 25 Jul 2016 Chemical structure information added
  • 11 Jul 2016 Launched for Bacterial meningitis in USA (IV)
  • 11 Jul 2016 Launched for Intra-abdominal infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top